Redox reversible bipyridyl-osmium complex conjugates
First Claim
Patent Images
1. An electrochemically detectable compound of the formula whereinR and R1 are the same or different and are 2,2′
- -bipyridyl, 4,4′
-disubstituted-2,2′
-bipyridyl, 5-5′
-disubstituted,-2,2′
-bipyridyl, 1,10-phenanthrolinyl, 4,7-disubstituted-1,10-phenanthrolinyl, or 5,6-disubstituted-1,10-phenanthrolinyl, wherein each substituent is a methyl, ethyl, or phenyl group, R5 is 4-substituted-2,2′
-bipyridyl or 4,4′
-disubstituted-2,2′
-bipyridyl wherein the 4-substituent is the group B—
(L)k—
Q(CH2)i— and
the 4′
-substituent is a methyl, ethyl or phenyl group;
R, R1 and R5 are coordinated to Os through their nitrogen atoms;
Q is O, S, or NR4 wherein R4 is hydrogen, methyl or ethyl;
—
L—
is a divalent linker;
k is 1 or 0;
i is 1, 2, 3, 4, 5 or 6;
B is hydrogen or a group comprising a ligand that binds to a specific binding partner;
d is +2 or +3;
X and Y are anions selected from monovalent anions chloride, bromide, iodide, fluoride, tetrafluoroborate, perchlorate, and nitrate and divalent anions sulfate, carbonate or sulfite wherein x and y are independently 0, 1, 2, or 3 so that the net charge of XxYy is −
2 or −
3.
4 Assignments
0 Petitions
Accused Products
Abstract
Novel bipyridyl-osmium complex conjugates, their preparation, and their use in electrochemical assays are described. The redox reversible-osmium complexes can be prepared to exhibit unique reversible redox potentials and can thus be used in combination with other electroactive redox reversible species having redox potentials differing by at least 50 millivolts in electrochemical assays designed for use of multiple electroactive species in the same cell and in the same sample without interference between the two or more redox coupled conjugate systems.
111 Citations
8 Claims
-
1. An electrochemically detectable compound of the formula
wherein R and R1 are the same or different and are 2,2′ - -bipyridyl, 4,4′
-disubstituted-2,2′
-bipyridyl, 5-5′
-disubstituted,-2,2′
-bipyridyl, 1,10-phenanthrolinyl, 4,7-disubstituted-1,10-phenanthrolinyl, or 5,6-disubstituted-1,10-phenanthrolinyl, wherein each substituent is a methyl, ethyl, or phenyl group,R5 is 4-substituted-2,2′
-bipyridyl or 4,4′
-disubstituted-2,2′
-bipyridyl wherein the 4-substituent is the group B—
(L)k—
Q(CH2)i— and
the 4′
-substituent is a methyl, ethyl or phenyl group;
R, R1 and R5 are coordinated to Os through their nitrogen atoms;
Q is O, S, or NR4 wherein R4 is hydrogen, methyl or ethyl;
—
L—
is a divalent linker;
k is 1 or 0;
i is 1, 2, 3, 4, 5 or 6;
B is hydrogen or a group comprising a ligand that binds to a specific binding partner;
d is +2 or +3;
X and Y are anions selected from monovalent anions chloride, bromide, iodide, fluoride, tetrafluoroborate, perchlorate, and nitrate and divalent anions sulfate, carbonate or sulfite wherein x and y are independently 0, 1, 2, or 3 so that the net charge of XxYy is −
2 or −
3.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
8. The detectable compound of claim 6 wherein B comprises a of the formula
- -bipyridyl, 4,4′
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeRoche Diabetes Care Inc. (Roche Holding AG)
-
Original AssigneeRoche Diagnostics Corporation (Roche Holding AG)
-
InventorsBuck, Harvey B. Jr., Deng, Zhi David
-
Primary Examiner(s)Le, Long V.
-
Assistant Examiner(s)GABEL, GAILENE
-
Application NumberUS09/322,791Time in Patent Office1,012 DaysField of Search435/4-6, 435/7.1, 435/7.25, 435/7.92, 435/7.93, 435/14, 435/25, 435/7.2, 422/82.01, 436/501, 436/536, 436/537, 436/56, 436/66, 436/164, 436/172, 436/543, 436/84, 436/547, 436/518, 436/548, 436/544, 436/805, 436/517, 436/806, 530/303, 530/304, 530/385US Class Current435/4CPC Class CodesC07F 15/0026 without a metal-carbon linkageC07K 14/805 Haemoglobins; MyoglobinsC07K 5/101 the side chain containing 2...C07K 7/02 Linear peptides containing ...C07K 7/06 having 5 to 11 amino acidsC07K 9/001 the peptide sequence having...G01N 2333/805 Haemoglobins; MyoglobinsG01N 2458/30 Electrochemically active la...G01N 27/3277 being a redox reaction, e.g...G01N 33/532 Production of labelled immu...G01N 33/536 with immune complex formed ...G01N 33/58 involving labelled substanc...G01N 33/723 Glycosylated haemoglobinY10S 436/805 Optical propertyY10S 436/806 Electrical property or magn...Y10T 436/105831 Protein or peptide standard...
